Clinical trials of levosimendan

TrialResults-center www.trialresultscenter.org

1 acute heart failure

Trial	Treatments	Patients	Trials design and methods
levosimendan vs placebo			
REVIVE-I , 2003 n=NA follow-up:	levosimendan 0.10.2 mg/kg/min versus placebo	patienst with HF andsymptoms at rest	Parallel groups
REVIVE II , 2013 [NCT00048425] n=299/301 follow-up: 5 days	Intravenous Levosimendan versus placebo	patients with decompensated chronic heart failure	Parallel groups double blind
RUSSLAN , 2002 n=NA follow-up: 14 days	Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h versus placebo	patients with left ventricular failure complicating acute myocardial infarction	Parallel groups double-blind
levosimendan vs dobutamine			
CASINO n=NA follow-up:	Levosimendan 16 mg/kg 0.2 mg/kg/min versus Dobutamine (10 mg/kg/min) and placebo	patients withdecompensatedlow-output HF	Parallel groups
LIDO , 2002 n=NA follow-up: 24h	Levosimendan versus Dobutamine	patients with low-output heart failure	Parallel groups double-blind
SURVIVE , 2007 [NCT00348504] n=664/663 follow-up: 180 days	Intravenous levosimendan versus intravenous dobutamine	patients hospitalized with acute decompensated heart failure who required inotropic support	Parallel groups double-blind 9 countries

More details and results :

- new drug under development for acute heart failure in all type of patients at http://www.trialresultscenter.org/go-Q640
- calcium sensitiser for acute heart failure in all type of patients at http://www.trialresultscenter.org/go-Q647

References

REVIVE-I, 2003:

Packer M, Colucci WS, Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. (Abstract) J Card Fail 2003;9:S61

Dickstein K, Snapinn S How should we analyse hospitalizations in clinical trials? Eur Heart J 2003 Jan;24:24-5 [12559935]

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T Effect of levosimendan on the short-termclinical course of patients with acutelydecompensated heart failure. JACC Heart Fail 2013;1:103-11 [24621834]

REVIVE II, 2013:

Packer M. The Randomized multicenter EValuation of IntravenousleVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials.

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T Effect of levosimendan on the short-termclinical course of patients with acutelydecompensated heart failure. JACC Heart Fail 2013 Apr;1:103-11 [24621834] 10.1016/j.jchf.2012.12.004

RUSSLAN, 2002:

Moiseyev VS, Pder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002 Sep;23:1422-32 [12208222]

CASINO, 0:

Zairis MN ACC 53rd Annual Scientific Session: Abstract 835-6.

LIDO, 2002:

Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002 Jul 20;360:196-202 [12133653]

SURVIVE, 2007:

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Pder P, Kivikko M Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 May 2;297:1883-91 [17473298]

Entry terms: simendan, OR-1855, Simadax, dextrosimendan, OR 1259, OR-1259,